Loading...
ROCO
6572
Market cap24mUSD
Jul 09, Last price  
7.55TWD
1D
-1.95%
1Q
1.21%
Jan 2017
-70.74%
IPO
-81.19%
Name

PlexBio Co Ltd

Chart & Performance

D1W1MN
ROCO:6572 chart
P/E
P/S
6.16
EPS
Div Yield, %
Shrs. gr., 5y
0.12%
Rev. gr., 5y
4.63%
Revenues
127m
-0.76%
0101,347,000124,942,000191,188,000167,176,000128,062,000127,095,000
Net income
-62m
L+1.36%
0-141,069,000-131,585,000-53,136,000-58,531,000-61,634,000-62,470,000
CFO
-79m
L+1,464.56%
0-110,791,000-84,332,000-71,445,000-29,267,000-5,056,000-79,104,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

PlexBio Co., Ltd. is dedicated to the creation and production of in vitro diagnostic (IVD) solutions for both molecular biology and immunology purposes. Their comprehensive product range features services for optimizing diagnostic workflows, as well as automated kits for sample preparation and extraction. A key innovation is their IntelliPlex platform, which leverages pCode technology to enable advanced, "sample-to-answer" multiplexing assays. The company also supplies specialized oncology panels designed for detecting lung cancer, gene mutations, and chromosomal rearrangements. Additionally, PlexBio offers a variety of infectious disease tests, including IntelliPlex kits for SARS-CoV-2 detection, influenza, and SARS-CoV-2 variant analysis, complemented by essential reagents such as pCode coupling buffer sets. Founded in 2009, PlexBio Co., Ltd. operates from its headquarters in Taipei, Taiwan.
IPO date
Feb 26, 2016
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT